🚨 Very excited to share my # IIT just prior to #ASH24 👉🏾 T-cell immune cluster analysis using CyTOF identifies unique subgroups... We found 2 unique immune clusters 👇🏽 among ND AML pts treated with VEN+HMA 1) immune depleted among responders 2) immune infiltrated in #TP53m #AML @MayoCancerCare #leusm

@EddieSantosMD @MayoCancerCare Thank you!🙏🏾

🚨 Happy to be a part of this trial: Vodobatinib for patients with Philadelphia chromosome-positive chronic... led by Dr. Cortes et al. @TheLancetHaem #CML #Ph_pos_disease 👇🏽 Significant activity in heavily treated Ph+ CML CP/BP including prior ponatinib. Major cytogenetic response 70%, 3 yrs PFS 80%.

@RenoHemonc It is too early to say based on these results. CMR rate (BCR-ABL1 <0.01) relatively low at 24%. Numbers and follow up is short.

📣 If any one would like to join interactive discussion on sequencing of TKI in CML! 👇🏽#CML #MedTwitter

@Zahra_Haj_Issa Thank you Zahra!

RT @MostafaFaisal14: Weekend 💎 💎 💎 about Ph like ALL by @TalhaBadarMD

#weekend_review 6/ Proposed treatment algorithm with targeted therapy for Ph like ALL: ABL directed TKI with chemotherapy for ABL class fusion (e.g. ABL1, ABL2, CSF1R, and PDGFRB). JAK inhibitor with chemotherapy for CRLF2/JAK pathways alteration. Ras pathway alteration, consider FLT3/MEK inhibitors. Ongoing studies utilizing targeted therapy combos (NCT03571321 with JAKi), (NCT03040030 with dasatinib), (NCT03834961 with TRKi)

#weekend_review 4/ Incidence of Ph like ALL, according to age: More common in AYA group and Hispanic ethnicity. DOI: 10.1056/NEJMc1412123

#weekend_review 2/ Ph like ALL Diagnostic algorithm to identify Ph like ALL: 1. Analysis of CRLF2 expression. 2. FISH analysis targeting ABL and JAK pathway activating fusions; ABL1, ABL2, CSF1R, PDGFRB & JAK2. 3. Fusion specific RT-PCR for the identification of the respective ABL and JAK fusion partner and sensitive MRD monitoring

Certainly will enjoy eating this cookie and chocolate! One of my patients with AML! Celebrating 3 yrs in remission on venetoclax plus azacitidine #endleukemia

RT @MostafaFaisal14: Weekend 💎 💎 💎 by @TalhaBadarMD

#weekend_review chemo-free regimen for Ph-ve B-cell ALL 4/ Summary 1. Inotuzumab is better induction/upfront strategy than blinatumomab. 2. "chemo-free" regimen might not be as effective in high risk ALL patients. 3. May need to intensify CNS prophylaxis, using "chemo-free" regimens.